✦ LIBER ✦

65 SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE – PREDICTIVE FACTORS FOR SEPSIS

✍ Scribed by Rutter, K.; Ferlitsch, A.; Maieron, A.; Stättermayer, A.F.; Graziadei, I.; Dulic, M.; Gschwantler, M.; Stauber, R.; Hofer, H.; Peck-Radosavljevic, M.; Vogel, W.; Trauner, M.; Ferenci, P.

Book ID: 123460063
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 62 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)60067-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Telaprevir or boceprevir triple therapy

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis

✍ Saxena, V.; Manos, M. M.; Yee, H. S.; Catalli, L.; Wayne, E.; Murphy, R. C.; Shv 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Sa1039 The Importance of Interleukin 28b

Sa1039 The Importance of Interleukin 28b Polymorphism for Prediction of Sustained Virologic Response in Chronic Hepatitis C Patients Treated With Triple Therapy Including Boceprevir or Telaprevir - A Meta-Analysis

✍ Bota, Simona; Sporea, Ioan; Sirli, Roxana; Neghina, Adriana; Popescu, Alina; Str 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 435 KB

P1200 EFFECTIVENESS OF TRIPLE THERAPY WI

P1200 EFFECTIVENESS OF TRIPLE THERAPY WITH BOCEPREVIR OR TELAPREVIR IN A MULTICENTRE CLINICAL PRACTICE COHORT OF HCV TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED HEPATIC FIBROSIS. SVR-12W AFTER TREATMENT

✍ Fernández, C.; Muñoz de Rueda, P.; Alonso, S.; Prieto, M.; Martín-Álvarez, A.; P 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Validation of a clinical index for predi

Validation of a clinical index for predicting risk of advanced liver disease in patients with chronic hepatitis C

✍ T.F. Imperiale; L.J. Born; D.C. Pound; A.R. Baluyut; P.Y. Kwo 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 35 KB

OC.03.1 EARLY DYNAMIC EVALUATION OF THE

OC.03.1 EARLY DYNAMIC EVALUATION OF THE NS3 HCV-GENOME REGION DURING TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1: PRELIMINARY RESULTS FROM THE SCANNER STUDY

✍ Di Paolo, D.; Ceccherini-Silberstein, F.; Cento, V.; Cucchiarelli, S.; Francioso 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Severity of liver disease predicts the d

Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy

✍ Wassim Chehadeh; Widad Al-Nakib 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

## Abstract A higher prevalence of glucose abnormalities has been reported in patients with hepatitis C virus (HCV) infection compared to patients with hepatitis B virus (HBV) infection. However, previous studies considered some confounding factors and ignored others, which might influence the comp